A C Arrieta1, J S Bradley. 1. Pediatric Infectious Diseases Division, Children's Hospital of Orange County, Orange, CA 92868, USA. aarrieta@CHOC.org
Abstract
BACKGROUND: Urinary tract infections (UTIs) are common in childhood. They represent a significant proportion (10%) of hospital-acquired infections in children. Bacteria causing UTIs in children vary, depending on the setting (community-acquired vs. nosocomial), underlying anatomic anomalies and concurrent medical conditions. OBJECTIVE: To review published and unpublished clinical studies that have used cefepime for the treatment of UTIs in children. METHODS AND RESULTS: In two recent multicenter, randomized trials, cefepime (50 mg/kg/dose every 8 h and every 12 h) was compared with ceftazidime (50 mg/kg/dose every 8 h) for the treatment of serious urinary tract infections including pyelonephritis in children less than 12 years of age. In these studies a favorable clinical and microbiologic response was observed in >95% of cefepime-treated and ceftazidime-treated children assessed at the end of treatment. CONCLUSIONS: These results indicate that cefepime represents an important therapeutic option for the treatment of serious UTIs in children.
BACKGROUND:Urinary tract infections (UTIs) are common in childhood. They represent a significant proportion (10%) of hospital-acquired infections in children. Bacteria causing UTIs in children vary, depending on the setting (community-acquired vs. nosocomial), underlying anatomic anomalies and concurrent medical conditions. OBJECTIVE: To review published and unpublished clinical studies that have used cefepime for the treatment of UTIs in children. METHODS AND RESULTS: In two recent multicenter, randomized trials, cefepime (50 mg/kg/dose every 8 h and every 12 h) was compared with ceftazidime (50 mg/kg/dose every 8 h) for the treatment of serious urinary tract infections including pyelonephritis in children less than 12 years of age. In these studies a favorable clinical and microbiologic response was observed in >95% of cefepime-treated and ceftazidime-treated children assessed at the end of treatment. CONCLUSIONS: These results indicate that cefepime represents an important therapeutic option for the treatment of serious UTIs in children.
Authors: Kensuke Shoji; John S Bradley; Michael D Reed; John N van den Anker; Christine Domonoske; Edmund V Capparelli Journal: Antimicrob Agents Chemother Date: 2016-03-25 Impact factor: 5.191
Authors: Christopher J Arnold; Jessica Ericson; Nathan Cho; James Tian; Shelby Wilson; Vivian H Chu; Christoph P Hornik; Reese H Clark; Daniel K Benjamin; P Brian Smith Journal: Pediatr Infect Dis J Date: 2015-09 Impact factor: 3.806